HC Wainwright Brokers Decrease Earnings Estimates for ATOS

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Stock analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Atossa Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.32) for the year, down from their previous forecast of ($0.21). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

A number of other brokerages also recently weighed in on ATOS. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th.

Atossa Therapeutics Stock Down 6.6 %

Shares of NASDAQ ATOS opened at $1.28 on Friday. The stock’s 50-day simple moving average is $1.44 and its two-hundred day simple moving average is $1.38. Atossa Therapeutics has a twelve month low of $0.65 and a twelve month high of $2.31. The firm has a market capitalization of $160.97 million, a P/E ratio of -5.82 and a beta of 1.23.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in Atossa Therapeutics during the 2nd quarter valued at $29,000. Intech Investment Management LLC bought a new position in Atossa Therapeutics in the third quarter worth about $29,000. SG Americas Securities LLC lifted its stake in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares during the period. Cetera Advisors LLC purchased a new position in Atossa Therapeutics during the first quarter valued at $72,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics during the 3rd quarter valued at about $75,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.